MedPath

Mobile Application Using the PRO-CTCAE to Improve Patients' Participation in Symptom Management During Treatment.

Not Applicable
Conditions
Neoplasms
Interventions
Other: ePRO-CTCAE application
Registration Number
NCT04568278
Lead Sponsor
Samsung Medical Center
Brief Summary

This study aims to evaluate the effect of a mobile application system using the Patient Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) to improve patients' participation in symptom management during cancer treatment. Our hypothesis is that patients who use a mobile application using the PRO-CTCAE will more likely to recognize symptoms due to cancer treatment and report them better to their clinicians than patients who do not use the mobile application.

Detailed Description

This is a randomized controlled trial to evaluate the effect of a mobile application system using the Patient Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) to improve patients' participation in symptom management during cancer treatment. Breast, lung, head and neck, esophagus, and gynecologic cancer patients who will begin new lines of chemotherapy or radiation therapy will be randomly assigned into the intervention and control groups (2:1 ratio). The intervention group will have the mobile application installed on their smart phones which they could record symptoms and adverse events due to cancer treatments using the pre-specified PRO-CTCAE questions for different types of cancer. The control group will have usual care. Primary endpoint is patients' participation/engagement of reporting symptoms and it will be evaluated at 8 weeks after the intervention using a questionnaire developed by the research team. Secondary end points are unexpected hospital visits during treatment during 8 weeks after the beginning of the treatment and quality of life at 8 weeks after the intervention.

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
222
Inclusion Criteria
  • Patients who are scheduled to have chemotherapy or radiation therapy.
  • Patients who own a smartphone (Android) and who can use mobile applications.
  • Patients who understand the purpose of this study and agree to participate in the study
  • Patients age over 18 years old (no age limit, but if necessary informed consent of the caregivers will be obtained for the patients whose age are over 70 years old)
Exclusion Criteria
  • Patients whose life expectancy is less than 6 months (hospice)
  • Patients who would any physical or mental problems that would make them difficult to use the applications

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Intervention GroupePRO-CTCAE applicationa mobile application using the PRO-CTCAE along with usual care
Primary Outcome Measures
NameTimeMethod
Patients' participation in symptom management8 weeks after the intervention

Patients' participation in reporting and managing symptoms due to cancer treatment will be measured using 7 questions developed by study team. Questions will be asked using 4 Likert scale. Minimum value is 0 and maximum value will be 21. Higher score means better outcome.

Secondary Outcome Measures
NameTimeMethod
European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire C-308 weeks after the intervention

State of well-being evaluated by an individual, including both physical, mental, social, and spiritual areas. This will be measured using relevant items of European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30. Scores will be calculated by manual (0-100) and higher score means better quality of life.

Unexpected visits8 weeks after the intervention

number of unexpected hospital visits (emergency room visits, unplanned outpatient visits, or unplanned hospitalization) due to symptoms or adverse events due to cancer treatment

Trial Locations

Locations (2)

Danbee Kang

🇰🇷

Seoul, Korea, Republic of

Samsung Medical Center

🇰🇷

Seoul, Korea, Republic of

© Copyright 2025. All Rights Reserved by MedPath